Circadian secretion pattern of melatonin in Parkinson's disease

Although several studies on the efficacy and the toxicity of exogenous melatonin in Parkinson patients have been carried out, there are no data available on melatonin secretion in these patients. We therefore performed a controlled trial in 9 Parkinson patients (aged 62.1 +/- 8.7 years, x +/- SD) an...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Neural Transmission - Parkinson's Disease and Dementia Section 1991-01, Vol.3 (1), p.41-47
Main Authors: FERTL, E, AUFF, E, DOPPELBAUER, A, WALDHAUSER, F
Format: Article
Language:English
Subjects:
Adult
Aged
Biological and medical sciences
Biomarkers
Circadian Rhythm - physiology
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Female
Humans
Levodopa - therapeutic use
Male
Medical sciences
Melatonin - blood
Melatonin - secretion
Middle Aged
Neurology
Parkinson Disease - drug therapy
Parkinson Disease - physiopathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although several studies on the efficacy and the toxicity of exogenous melatonin in Parkinson patients have been carried out, there are no data available on melatonin secretion in these patients. We therefore performed a controlled trial in 9 Parkinson patients (aged 62.1 +/- 8.7 years, x +/- SD) and in 14 control persons (58.0 +/- 10.4 years). Parkinson patients were treated with l-dopa (300-1000 mg per day) in combination with a peripheral decarboxylase inhibitor (benserazide, carbidopa). 14 venous blood samples were taken from each person during a period of 24 hours in order to investigate the circadian secretion pattern of melatonin. Serum melatonin levels were estimated by radioimmuno assay. We found that the circadian secretion patterns of l-dopa-treated Parkinson patients and age-matched controls were very similar except for a phase advance of the nocturnal melatonin elevation in the parkinsonian group.
ISSN:0936-3076
1435-1463
DOI:10.1007/BF02251135